Progesterone receptor in non-small cell lung cancer - A potent prognostic factor and possible target for endocrine therapy

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6450-6458

  Ishibashi, Hironori ^a,b   Suzuki, Takashi ^a   Suzuki, Satoshi ^b   Niikawa, Hiromichi ^a,b   Lu, Liangying ^a   Miki, Yasuhiro ^a   Moriya, Takuya ^a   Hayashi, Shin Ichi ^a   Handa, Masashi ^c   Kondo, Takashi ^b   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c SENDAI KOUSEI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; CYCLIN A; CYCLIN E; ENZYME; KI 67 ANTIGEN; LUCIFERASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENDER; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; PROGESTERONE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22244486655     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3087     Document Type: Article

References (45)

1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics. 2004. CA Cancer J Clin 2004;54:8-29.
2. Jemal A, Chu KC, Tarone RE. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst 2001;93:277-83.
3. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 2000;161:1355-67.
4. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
5. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
6. Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 1997;3:1005-8.
7. Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 1997;11:1593-607.
8. Musgrove EA, Hunter LJ, Lee CS, Swarbrick A, Hui R, Sutherland RL. Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2. J Biol Chem 2001;276:47675-83.
9. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-65.
10. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736-44.
11. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res 1996;16:3803-6.
12. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64.
13. Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000;124:1467-70.
14. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 2001;285:340-7.
15. Clark BJ, Combs R, Hales KH, Hales DB, Stocco DM. Inhibition of transcription affects synthesis of steroidogenic acute regulatory protein and steroidogenesis in MA-10 mouse Leydig tumor cells. Endocrinology 1997;138:4893-901.
16. Sasano H, Nagura H, Harada N, Goukon Y, Kimura M. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 1994;25:530-5.
17. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
18. Yamashita J, Tashiro K, Yoneda S, Kawahara K, Shirakusa T. Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Chest 1996;109:1328-34.
19. Imai M, Nakamura T, Akiyama T, Horii A. Infrequent somatic mutations of the ICAT gene in various human cancers with frequent Ip-LOH and/or abnormal nuclear accumulation of β-catenin. Oncol Rep 2004;12:1099-103.
20. Shibahara S, Yoshizawa M, Suzuki H, Takeda K, Meguro K, Endo K. Functional analysis of cDNAs for two types of human heme oxygenase and evidence for their separate regulation. J Biochem (Tokyo) 1993;113:214-8.
21. Savouret JF, Fridlanski F, Atger M, Misrahi M, Berger R, Milgrom E. Origin of the high constitutive level of progesterone receptor in T47-D breast cancer cells. Mol Cell Endocrinol 1991;75:157-62.
22. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J, Lupu R. Expression and regulation of estrogen receptor β in human breast tumors and cell lines. Oncol Rep 2000;7:157-67.
23. Kodama T, Shimizu N, Yoshikawa N, et al. Role of the glucocorticoid receptor for regulation of hypoxia-dependent gene expression. J Biol Chem 2004;278:33384-91.
24. Saj S, Okumura N, Eguchi H, et al. MDM2 enhances the function of estrogen receptor α in human breast cancer cells. Biochem Biophys Res Commun 2001;281:259-65.
25. Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H, Hayashi S. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 2002;192:93-104.
26. Lopezde Alda MJ, Barcelo D. Use of solid-phase extraction in various of its modalities for sample preparation in the determination of estrogens and progestogens in sediment and water. J Chromatogr A 2001;938:145-53.
27. Clarke CL, Zaino RJ, Feil PD, et al. Monoclonal antibodies to human progesterone receptor: characterization by biochemical and immunohistochemical techniques. Endocrinology 1987;121:1123-32.
28. Nakamura Y, Igarashi K, Suzuki T, et al. E4F1, a novel estrogen-responsive gene in possible atheroprotection, revealed by microarray analysis. Am J Pathol 2004;165:2019-31.
29. Wiechert R, Neef G. Synthesis of antiprogestational steroids. J Steroid Biochem 1987;27:851-8.
30. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 1978;253:2223-8.
31. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB. Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 2003;8:257-68.
32. Baulieu EE, Robel P. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol 1990;37:395-403.
33. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 1984;54:1802-13.
34. Lee WS, Liu CW, Juan SH, Liang YC, Ho PY, Lee YH. Molecular mechanism of progesterone-induced anti-proliferation in rat aortic smooth muscle cells. Endocrinology 2003;144:2785-90.
35. Caputi M, Esposito V, Baldi A. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998;18:213-7.
36. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
37. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998;153:963-72.
38. Murphy LC, Alkhalaf M, Dotzlaw H, Coutts A. Haddad-Alkhalaf B. Regulation of gene expression in T-47D human breast cancer cells by progestins and antiprogestins. Hum Reprod 1994;1:174-80.
39. 3H]thymidine incorporation in human endometrial cancer cells. J Steroid Biochem 1988;31:131-5.
40. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-22.
41. Pannuti F, Camaggi CM, Strocchi E, Martoni A. MPA at high doses in advanced breast cancer: a statistical evaluation. Chemioterapia 1986;5:159-63.
42. Martoni A, Longhi A, Canova N, Pannuti F. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology 1991;48:1-6.
43. Nishimura R, Nagao K, Matsuda M, et al. Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer. Eur J Cancer 1991;33:1407-12.
44. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-4.
45. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors α and β in human lung tissue and cell lines. Lung Cancer 2000;37:153-9.